<p>Merus N.V.（NASDAQ:MRUS - 获取免费报告）在周五的午盘交易中，股价达到了新的 52 周高点。该股最高交易价格为 63.43 美元，最后交易价格为 63.26 美元，成交量为 1,061,420 股。该股此前收盘价为 61.44 美元。</p>
<h2>华尔街分析师观点</h2>
<p>MRUS 最近成为多份分析师报告的主题。富国银行将 Merus 的目标股价从 91.00 美元下调至 89.00 美元，并在 5 月 8 日的研究报告中给予该公司 “超配” 评级。古根海姆在 3 月 28 日的研究报告中重申了 “买入” 评级，并设定了 109.00 美元的目标股价。威廉·布莱尔在 4 月 28 日的研究报告中重新发布了 Merus 的 “跑赢大盘” 评级。Needham &amp; Company LLC 在 5 月 19 日的研究报告中重新发布了 “买入” 评级，并设定了 75.00 美元的目标股价。最后，BMO 资本市场在 5 月 23 日的研究报告中设定了 110.00 美元的目标股价，并给予该公司 “跑赢大盘” 评级。一位股票研究分析师给予该股 “持有” 评级，十二位给予 “买入” 评级，两位给予 “强烈买入” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “买入”，平均目标股价为 84.64 美元。</p>
<p><strong>阅读我们关于 Merus 的最新研究报告</strong></p>
<h2>Merus 股价上涨 3.0%</h2>
<p>该公司的 50 日简单移动平均线为 52.03 美元，200 日简单移动平均线为 46.02 美元。该公司的市值为 43.8 亿美元，市盈率为-15.50，贝塔值为 1.00。</p>
<p>Merus（NASDAQ:MRUS - 获取免费报告）最近于 5 月 14 日发布了季度财报。这家生物技术公司报告本季度每股收益为-1.40 美元，低于分析师一致预期的-1.17 美元，差距为 0.23 美元。Merus 的股本回报率为-35.99%，净利润率为-506.73%。该公司本季度的收入为 2649 万美元，而分析师预期为 782 万美元。卖方分析师预测 Merus N.V.在当前财年将发布-3.85 的每股收益。</p>
<h2>Merus 内部活动</h2>
<p>在其他消息中，首席运营官 Peter B. Silverman 于 6 月 20 日出售了 34,000 股 Merus 股票。股票以平均价格 52.76 美元出售，总价值为 1,793,840.00 美元。该交易在向 SEC 提交的法律文件中披露，相关文件可以通过此链接访问。在过去 90 天内，内部人士已出售 57,500 股公司股票，价值为 3,086,340 美元。内部人士持有公司 4.57% 的股份。</p>
<h2>对 Merus 的对冲基金观点</h2>
<p>一些机构投资者最近调整了他们对 MRUS 的持股。Boxer Capital Management LLC 在第四季度收购了 Merus 的新头寸，价值为 79,895,000 美元。Paradigm Biocapital Advisors LP 在第一季度将其在 Merus 的持股增加了 99.4%。Paradigm Biocapital Advisors LP 现在拥有 3,369,699 股生物技术公司的股票，价值为 141,831,000 美元，此前在该期间内又购买了 1,679,777 股。Wellington Management Group LLP 在第一季度将其在 Merus 的持股增加了 34.9%。Wellington Management Group LLP 现在拥有 4,718,172 股生物技术公司的股票，价值为 198,588,000 美元，此前在该期间内又购买了 1,220,519 股。Avoro Capital Advisors LLC 在第四季度将其在 Merus 的持股增加了 56.8%。Avoro Capital Advisors LLC 现在拥有 2,125,000 股生物技术公司的股票，价值为 89,356,000 美元，此前在该期间内又购买了 770,000 股。最后，Westfield Capital Management Co. LP 在第一季度将其在 Merus 的持股增加了 51.2%。Westfield Capital Management Co. LP 现在拥有 1,501,220 股生物技术公司的股票，价值为 63,186,000 美元，此前在该期间内又购买了 508,063 股。96.14% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Merus</h2>
<p>（获取免费报告）</p>
<p>Merus N.V.是一家临床阶段的免疫肿瘤学公司，专注于在荷兰开发抗体治疗。其双特异性抗体候选药物管线包括 Zenocutuzumab（MCLA-128），该药物正在进行针对转移性乳腺癌和去势抵抗性前列腺癌患者的二期临床试验，同时也在进行针对携带 Neuregulin 1 的实体肿瘤的 1/2 期临床试验。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票而非 Merus</li>
<li>股票分红削减发生，你准备好了吗？</li>
<li>2025 年：智能眼镜的关键一年，Meta 投资 Ray-Ban</li>
<li>深入了解买卖差价</li>
<li>Unity 的新广告解决方案推动股票达到 52 周高点</li>
<li>什么是盈利惊喜？</li>
<li>为什么雅培实验室是 2025 年第二季度的买入：增长与收益</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Merus 吗？</h2>
<p>在你考虑 Merus 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前立即购买……而 Merus 并不在名单上。</p>
<p>虽然 Merus 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

MRUS

<p>Merus N.V.（纳斯达克代码：MRUS）在交易中达到新的 52 周高点 63.43 美元，收盘价为 63.26 美元。分析师们的看法不一，富国银行将其目标价下调至 89 美元，而古根海姆则维持 109 美元的目标价。该公司报告季度每股亏损 1.40 美元，未能达到预期，但收入为 2649 万美元。内部人士出售股票和显著的机构投资引起关注，96.14% 的股份由机构投资者持有。Merus 专注于开发用于癌症治疗的抗体疗法</p>

<p>Merus N.V. (NASDAQ:MRUS - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $63.43 and last traded at $63.26, with a volume of 1061420 shares traded. The stock had previously closed at $61.44.</p>
<div class="lb-trans"><p>Merus N.V.（NASDAQ:MRUS - 获取免费报告）在周五的午盘交易中，股价达到了新的 52 周高点。该股最高交易价格为 63.43 美元，最后交易价格为 63.26 美元，成交量为 1,061,420 股。该股此前收盘价为 61.44 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>MRUS has been the subject of a number of recent analyst reports. Wells Fargo &amp; Company dropped their price target on shares of Merus from $91.00 to $89.00 and set an &#34;overweight&#34; rating for the company in a research report on Thursday, May 8th. Guggenheim reiterated a &#34;buy&#34; rating and set a $109.00 price target on shares of Merus in a research report on Friday, March 28th. William Blair reissued an &#34;outperform&#34; rating on shares of Merus in a research note on Monday, April 28th. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and issued a $75.00 price objective on shares of Merus in a research note on Monday, May 19th. Finally, BMO Capital Markets set a $110.00 price objective on shares of Merus and gave the company an &#34;outperform&#34; rating in a research note on Friday, May 23rd. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of &#34;Buy&#34; and an average target price of $84.64.</p>
<div class="lb-trans"><p>MRUS 最近成为多份分析师报告的主题。富国银行将 Merus 的目标股价从 91.00 美元下调至 89.00 美元，并在 5 月 8 日的研究报告中给予该公司 “超配” 评级。古根海姆在 3 月 28 日的研究报告中重申了 “买入” 评级，并设定了 109.00 美元的目标股价。威廉·布莱尔在 4 月 28 日的研究报告中重新发布了 Merus 的 “跑赢大盘” 评级。Needham &amp; Company LLC 在 5 月 19 日的研究报告中重新发布了 “买入” 评级，并设定了 75.00 美元的目标股价。最后，BMO 资本市场在 5 月 23 日的研究报告中设定了 110.00 美元的目标股价，并给予该公司 “跑赢大盘” 评级。一位股票研究分析师给予该股 “持有” 评级，十二位给予 “买入” 评级，两位给予 “强烈买入” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “买入”，平均目标股价为 84.64 美元。</p>
</div><p><strong>Read Our Latest Research Report on Merus</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Merus 的最新研究报告</strong></p>
</div><h2>Merus Stock Up 3.0%</h2>
<div class="lb-trans"><h2>Merus 股价上涨 3.0%</h2>
</div><p>The business's fifty day simple moving average is $52.03 and its two-hundred day simple moving average is $46.02. The company has a market cap of $4.38 billion, a price-to-earnings ratio of -15.50 and a beta of 1.00.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 52.03 美元，200 日简单移动平均线为 46.02 美元。该公司的市值为 43.8 亿美元，市盈率为-15.50，贝塔值为 1.00。</p>
</div><p>Merus (NASDAQ:MRUS - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). Merus had a negative return on equity of 35.99% and a negative net margin of 506.73%. The company had revenue of $26.49 million for the quarter, compared to analyst estimates of $7.82 million. Sell-side analysts predict that Merus N.V. will post -3.85 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Merus（NASDAQ:MRUS - 获取免费报告）最近于 5 月 14 日发布了季度财报。这家生物技术公司报告本季度每股收益为-1.40 美元，低于分析师一致预期的-1.17 美元，差距为 0.23 美元。Merus 的股本回报率为-35.99%，净利润率为-506.73%。该公司本季度的收入为 2649 万美元，而分析师预期为 782 万美元。卖方分析师预测 Merus N.V.在当前财年将发布-3.85 的每股收益。</p>
</div><h2>Insider Activity at Merus</h2>
<div class="lb-trans"><h2>Merus 内部活动</h2>
</div><p>In other news, COO Peter B. Silverman sold 34,000 shares of Merus stock in a transaction on Friday, June 20th. The shares were sold at an average price of $52.76, for a total value of $1,793,840.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 57,500 shares of company stock valued at $3,086,340. Insiders own 4.57% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席运营官 Peter B. Silverman 于 6 月 20 日出售了 34,000 股 Merus 股票。股票以平均价格 52.76 美元出售，总价值为 1,793,840.00 美元。该交易在向 SEC 提交的法律文件中披露，相关文件可以通过此链接访问。在过去 90 天内，内部人士已出售 57,500 股公司股票，价值为 3,086,340 美元。内部人士持有公司 4.57% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Merus</h2>
<div class="lb-trans"><h2>对 Merus 的对冲基金观点</h2>
</div><p>A number of institutional investors have recently modified their holdings of MRUS. Boxer Capital Management LLC acquired a new position in Merus in the 4th quarter valued at $79,895,000. Paradigm Biocapital Advisors LP increased its stake in Merus by 99.4% in the 1st quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company's stock valued at $141,831,000 after buying an additional 1,679,777 shares during the period. Wellington Management Group LLP increased its stake in Merus by 34.9% in the 1st quarter. Wellington Management Group LLP now owns 4,718,172 shares of the biotechnology company's stock valued at $198,588,000 after buying an additional 1,220,519 shares during the period. Avoro Capital Advisors LLC increased its stake in Merus by 56.8% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,125,000 shares of the biotechnology company's stock valued at $89,356,000 after buying an additional 770,000 shares during the period. Finally, Westfield Capital Management Co. LP increased its stake in Merus by 51.2% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,501,220 shares of the biotechnology company's stock valued at $63,186,000 after buying an additional 508,063 shares during the period. 96.14% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近调整了他们对 MRUS 的持股。Boxer Capital Management LLC 在第四季度收购了 Merus 的新头寸，价值为 79,895,000 美元。Paradigm Biocapital Advisors LP 在第一季度将其在 Merus 的持股增加了 99.4%。Paradigm Biocapital Advisors LP 现在拥有 3,369,699 股生物技术公司的股票，价值为 141,831,000 美元，此前在该期间内又购买了 1,679,777 股。Wellington Management Group LLP 在第一季度将其在 Merus 的持股增加了 34.9%。Wellington Management Group LLP 现在拥有 4,718,172 股生物技术公司的股票，价值为 198,588,000 美元，此前在该期间内又购买了 1,220,519 股。Avoro Capital Advisors LLC 在第四季度将其在 Merus 的持股增加了 56.8%。Avoro Capital Advisors LLC 现在拥有 2,125,000 股生物技术公司的股票，价值为 89,356,000 美元，此前在该期间内又购买了 770,000 股。最后，Westfield Capital Management Co. LP 在第一季度将其在 Merus 的持股增加了 51.2%。Westfield Capital Management Co. LP 现在拥有 1,501,220 股生物技术公司的股票，价值为 63,186,000 美元，此前在该期间内又购买了 508,063 股。96.14% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Merus</h2>
<div class="lb-trans"><h2>关于 Merus</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.</p>
<div class="lb-trans"><p>Merus N.V.是一家临床阶段的免疫肿瘤学公司，专注于在荷兰开发抗体治疗。其双特异性抗体候选药物管线包括 Zenocutuzumab（MCLA-128），该药物正在进行针对转移性乳腺癌和去势抵抗性前列腺癌患者的二期临床试验，同时也在进行针对携带 Neuregulin 1 的实体肿瘤的 1/2 期临床试验。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Merus</li>
<li>Stock Dividend Cuts Happen Are You Ready?</li>
<li>2025: A Pivotal Year for Smart Glasses As Meta Invests in Ray-Ban</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>Unity’s New Ad Solutions Drive Stock to 52-Week High</li>
<li>What is an Earnings Surprise?</li>
<li>Why Abbott Laboratories Is a Q2 2025 Buy: Growth &amp; Yield</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非 Merus</li>
<li>股票分红削减发生，你准备好了吗？</li>
<li>2025 年：智能眼镜的关键一年，Meta 投资 Ray-Ban</li>
<li>深入了解买卖差价</li>
<li>Unity 的新广告解决方案推动股票达到 52 周高点</li>
<li>什么是盈利惊喜？</li>
<li>为什么雅培实验室是 2025 年第二季度的买入：增长与收益</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Merus Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Merus 吗？</h2>
</div><p>Before you consider Merus, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Merus 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前立即购买……而 Merus 并不在名单上。</p>
</div><p>While Merus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Merus 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Merus（NASDAQ:MRUS）创下新的 12 个月高点 - 以下是原因